|
|
||||||||
1 Division of Cardiothoracic
Surgery, The use of
Mg2+-supplemented hyperkalemic
cardioplegia preserves microvascular function. However, the mechanism
of this beneficial action remains to be elucidated. We investigated the
effects of Mg2+ supplementation on
the regulation of intracellular calcium concentration ([Ca2+]i)
and vascular function using an in vitro microvascular model. Ferret
coronary arterioles (80-150 µm in diameter) were studied in a
pressurized (40 mmHg) no-flow, normothermic (37°C) state. Simultaneous monitoring of internal luminal diameter and
[Ca2+]i
using fura 2 were made with microscopic image analysis. The microvessels (n = 6 each group) were
divided into four groups according to the content of
MgCl2 (nominally 0, 1.2, 5.0, and 25.0 mM) in a hyperkalemic cardioplegic solution
([K+] 25.0 mM). After
baseline measurements, vessels were subjected to 60 min of hypoxia with
hyperkalemic cardioplegia (equilibrated with 95%
N2-5%
CO2) containing each
concentration of Mg2+
([Mg2+]) and were then
reoxygenated. During hyperkalemic cardioplegia, [Ca2+]i
increased in a time-dependent manner in all groups. In the lower
[Mg2+] cardioplegia
groups,
[Ca2+]i
was significantly increased at the end of the 60-min cardioplegic period (247 ± 44 nM and 236 ± 49 nM in
[Mg2+] 0 and 1.2 mM
groups, respectively; both P < 0.05 vs. baseline) with 19.6-17.2% vascular contraction. Conversely,
there was no significant
[Ca2+]i
increase in the higher
[Mg2+] cardioplegia
groups and less vascular contraction (5.4-4.1%, both
P < 0.05 vs.
[Mg2+] 1.2 mM group).
After reperfusion, agonist (U-46619, thromboxane A2 analog)-induced vascular
contraction was significantly enhanced in the lower
[Mg2+] cardioplegia
groups (both P < 0.05 vs. control)
but was normalized in the higher
[Mg2+] cardioplegia
groups. Intrinsic myogenic contraction was significantly decreased in
the lower [Mg2+]
cardioplegia groups (both P < 0.05 vs. control) but was preserved in the higher
[Mg2+] cardioplegia
groups. These results suggest that supplementation of the solution with
>5.0 mM [Mg2+] may
prevent hyperkalemic cardioplegia-related intracellular Ca2+ overloading and preserve
vascular contractile function in coronary microvessels.
cardioplegia; coronary microvessel; vasospasm
THE CORONARY MICROCIRCULATION plays a central role in
the regulation of myocardial perfusion, which in turnmay affect
myocardial contractile function. Recently, the influence of various
surgical cardioplegic solutions on coronary microvascular function has received attention. Hyperkalemic cardioplegic solutions have been used
to achieve cardiac arrest and to protect the myocardium during cardiac
operations. However, there is abundant evidence that ischemic cardiac
arrest using a hyperkalemic cardioplegic solution significantly changes
the response of coronary microvessels to various vasoactive agents (13,
15, 20, 25). The pathophysiology underlying this hyperkalemic
cardioplegia-related microvascular dysfunction is likely to be
multifactorial and, at present, not fully understood. However,
intracellular calcium
([Ca2+]i)
overloading in coronary vascular smooth muscle could play a critical
role in the development of microvascular dysfunction. The cellular
mechanism of Ca2+ accumulation has
been related, in part, to the high
K+ concentration and insufficient
oxygen supply in conventional crystalloid cardioplegic solutions.
It is well known that magnesium is an important ionic modulator of
blood vessel tone. Indeed, Mg2+
has been characterized as an endogenous calcium channel
blocker that relaxes vascular smooth muscle and attenuates the
vasoconstriction induced by several vasoactive drugs (1). The
importance of Mg2+ in
cardioplegic solutions has been increasingly recognized in the
maintenance of myocardial function after surgical ischemia (5,
8, 24). Recently, we demonstrated that hypermagnesium cardioplegia can
preserve coronary microvascular function after surgical cardiac arrest
compared with a magnesium-free hyperkalemic cardioplegic solution (23).
However, the molecular basis for the action of magnesium in the
vascular system is not well known. The relationship between
extracellular Mg2+ concentration
([Mg2+]) and
[Ca2+]i
during or after hyperkalemic cardioplegia has not yet been well characterized.
To simultaneously assess both intracellular
Ca2+ changes in coronary smooth
muscle cells and microvascular function, we established an in vitro
microvascular model that could simulate the regulation of
coronary microcirculation under reduced oxygen supply with crystalloid cardioplegia in the operating room. The aim of the present study was to investigate the effects of
Mg2+ supplementation on
[Ca2+]i
regulation in coronary microvessels and vascular function
during and after hyperkalemic cardioplegia.
Isolated Microvessel Preparations
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES
![]()
METHODS AND MATERIALS
TOP
ABSTRACT
INTRODUCTION
METHODS AND MATERIALS
RESULTS
DISCUSSION
REFERENCES
6 M) in microvessels
precontracted with potassium ions (20 mM).
All of the animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1985).
Measurements
Intraluminal diameter measurement. The vessels were pressurized to 40 mmHg in a no-flow state using a burette manometer filled with Krebs-PSS. The internal luminal diameter was measured with a video-monitored microscopic system (model KP-115, Zeiss IM35 and Hitachi CCD TV camera). The calibration of the measurement was performed using an 80-µm tungsten wire. The minimum resolution of the system was 1.5 µm.[Ca2+]i
measurement.
[Ca2+]i
of coronary microvascular smooth muscle was measured using
calcium-sensitive fluorescent dye fura 2. Coronary microvessels in the
tissue chamber were loaded with 5 µm acetoxymethyl ester of fura 2 (fura 2-AM) in Krebs-PSS containing 0.05% dimethyl sulfoxide and
0.01% Pluronic F-127. The loading time was 45 min followed by a 30-min
wash period at 37°C. The objective lens used was a Nikon Fluor
×40 (NA 0.8). To avoid the influence of fluorescent signals from
the endothelium, optimal focus was adjusted to the middle of the
microvascular smooth muscle layer by viewing the microvascular wall
under a bright microscopic field. Excitation light at 350 ± 5 and
390 ± 6 nm was used. Emission at 510 ± 24 nm was monitored with
a photomultiplier tube (Hamamatsu R928) and digitized by a Data
Acquisition-EZ A/D Converter. The digital signal of the two wavelengths
was processed using a program written using the DTVee version 3.0 programming environment (Data Translation). [Ca2+]i
was estimated from the ratio (R) of measured fluorescence signals (F)
elicited at two wavelengths according to the equation: R = (F350mv
F350bg)/(F390mv
F390bg), where
F350mv and
F390mv are the total measured
fluorescence of the microvessels at wavelengths of 350 and 390 nm,
respectively, and F350bg and
F390bg are the background
fluorescence signals at the respective wavelengths. The background
signals were measured on microvessels before fura 2-AM was loaded.
Particular care was taken to minimize possible photobleaching of fura 2 molecules.
Quantification of
[Ca2+]i.
With the ratio method applied, intermicrovascular differences in fura 2 loading, microvascular thickness, light path length, and camera gain
were canceled; therefore, the ratio values reflected true
[Ca2+]i
differences. For quantification of
[Ca2+]i,
we used an in situ dual-wavelength calibrating equation of Grynkiewicz
et al. (7):
[Ca2+]i = Kd [(R
Rmin)/(Rmax
R)]
, where
Kd (224 nM) is
the effective dissociation constant,
is the ratio of the
fluorescence at 390 nm with 0 Ca2+
to the 390 nm fluorescence with 1.2 mM
Ca2+. The maximum fluorescence
ratio (Rmax) of fura 2 is
observed when the dye is completely bound by
Ca2+ in a solution containing 1.2 mM CaCl2 plus 50 µm
4-bromo-A23187. After that, EGTA (5 mM) was added to achieve the
minimum fluorescence ratio
(Rmin). In these in situ
calibration experiments, Rmin was highly consistent and reproducible with little variation;
Rmax, however, was more variable.
Values from the in situ microvessel calibration were
Rmin = 0.35, Rmax = 1.22, and
= 1.10.
Experimental Protocols
After a 60-min stabilizing period, measurements of [Ca2+]i and internal luminal diameter were taken (baseline control). Microvessels were divided into four groups according to the content of MgCl2 (nominally 0, 1.2, 5.0, and 25.0 mM) in hypoxic, hyperkalemic cardioplegic solution. Hypoxia was induced by switching bubbling gas from 95% O2-5% CO2 to 95% N2-5% CO2. The composition of hyperkalemic cardioplegic solution was (in mM) 121 NaCl, 25 KCl, 12 NaHCO3, 1.2 CaCl2, and 11.1 glucose; pH 7.45, oxygen tension 5-30 mmHg. True anoxic condition was not achieved because a small amount of oxygen continuously diffused into the hyperkalemic cardioplegia from the atmosphere. The temperature was maintained at 37°C. All microvessels were subjected to 60 min of hypoxic, hyperkalemic cardioplegic solutions with each concentration of MgCl2 and then reperfused with oxygenated Krebs-PSS for 60 min. During 60 min of hypoxic, hyperkalemic cardioplegia and after 60 min of normoxic reperfusion, [Ca2+]i and internal luminal diameter were measured every 15 min. After 60 min of reperfusion, a cumulative concentration-response curve to a stable thromboxane A2 analog (U-46619, 10
9-10
6
M) was constructed to evaluate the agonist-induced vascular
contractility. The vessels were washed with a drug-free Krebs-PSS for
30 min. After the vessels were equilibrated for at least 30 min, the
active pressure-diameter relation was studied. Initially, the pressure was reduced to 10 mmHg to stabilize for 10 min. Then the pressure was
increased in increments of 10 mmHg up to 100 mmHg. At each pressure
increment, the change in internal luminal diameter was measured after
microvessel diameter had stabilized (generally after 3 min). Once the
determination of the active pressure-diameter relation was completed,
the pressure was returned to 50 mmHg, and finally, papaverine (100 µM) was applied in the tissue chamber to normalize the vascular
diameter. The normalized diameter was defined as the ratio of the
diameter observed at a given transmural pressure to the diameter of the
same vessel at 50 mmHg pressure in the presence of papaverine.
To test the osmotic influence of supplemented MgCl2 in the hyperkalemic cardioplegic solutions, a subset (n = 6) of experiments was performed in which adequate sucrose was added to the 1.2 mM [Mg] group to raise the osmolarity equal to that in the 25 mM [Mg] group (390-400 mosmol/l).
Drugs
Fura 2-AM and Pluronic F-127 were obtained from Molecular Probes (Eugene, OR). U-46619 was purchased from Sigma Chemical (St. Louis, MO). Papaverine was obtained from Eli Lilly (Indianapolis, IN). All solutions were prepared on the day of the study.Statistical Analysis
The response of microvessels to each intervention was examined only once in each animal. Therefore, each animal served as one sample, and n refers to the number of animals from which microvessels were taken in all experiments. In the microvessel contraction experiments, vessels not having cardioplegic intervention were taken as control, and changes in internal luminal diameter were expressed as the percent contraction of the baseline diameter. Results are expressed as means ± SE. The paired Student's t-test was applied for within-group comparisons with baseline. ANOVA followed by a multiple-comparison Fisher's test was used to test the differences among groups with different interventions (StatView 4.0; Abacus Concepts, Berkeley, CA). The probability was considered to be significant if the P value was <0.05.| |
RESULTS |
|---|
|
|
|---|
Characterization of Isolated Coronary Microvessels
Before exposure of microvessels to hyperkalemic cardioplegia, there were no significant differences in either the baseline vascular diameter or [Ca2+]i in smooth muscle among the four groups (vascular diameter: 102 ± 15 to 116 ± 18 µm; [Ca2+]i: 74 ± 17 to 79 ± 22 nM). After reperfusion, there were no significant differences in the papaverine-applied vascular diameter among the groups (115 ± 19 to 126 ± 16 µm).With respect to the osmotic influence of hyperkalemic cardioplegia ([Mg] 1.2 mM), the sucrose-added cardioplegia caused changes in microvascular diameter and [Ca2+]i similar to the no-sucrose-added cardioplegia (peak vascular contraction during cardioplegia: 15.6 ± 2.8% vs. 17.2 ± 3.6%; peak [Ca2+]i during cardioplegia: 218 ± 50 vs. 236 ± 49 nM; sucrose added vs. no sucrose added, respectively; both P > 0.05). These observations effectively ruled out a nonspecific osmotic effect of increased concentration of MgCl2 in the present study protocols.
Intracellular Ca2+ Dynamics
Figure 1 shows time-course dynamics in [Ca2+]i during and after hyperkalemic cardioplegia. On exposure to the hyperkalemic cardioplegic solution, [Ca2+]i in the lower [Mg2+] groups increased gradually in a time-dependent manner, and these increases were significantly different from the baseline level at the end of the 60-min cardioplegic period (247 ± 44 and 236 ± 49 nM, in [Mg2+] 0 and 1.2 mM groups, respectively; both P < 0.01 vs. baseline; between-group differences were not significant). However, a slight increase in the [Ca2+]i occurred in the higher [Mg2+] groups during hyperkalemic cardioplegia, but these increases were not statistically significant compared with the baseline value (102 ± 35 and 86 ± 27 nM, in [Mg2+] 5.0 and 25.0 mM groups, respectively; both P > 0.05 vs. baseline). After reperfusion with oxygenated Krebs-PSS, the [Ca2+]i returned to its baseline level within 15 min in all groups.
|
Changes in Diameter
As shown in Fig. 2, in the lower [Mg2+] groups percent contraction increased gradually during the cardioplegic period, and at the end of the 60-min cardioplegic period the percent contraction reached 19.6 ± 4.2% and 17.2 ± 3.6% in 0 and 1.2 mM [Mg2+] groups, respectively. In the higher [Mg2+] groups, percent contraction reached a maximum level within the initial 15 min of cardioplegia, which sustained during the cardioplegic period. The peak values were 5.4 ± 2.0% and 4.1 ± 1.7% in 5.0 and 25.0 mM [Mg2+] groups, respectively (both P < 0.05 vs. [Mg2+] 0 and 1.2 mM groups). After reperfusion, the vascular diameter recovered to its initial value within 15 min of reperfusion in all groups.
|
Vascular Contractility After Reperfusion
The agonist-induced contractile responses to U-46619 were significantly increased in the 0 and 1.2 mM [Mg2+] groups (both P < 0.05 vs. control), whereas those in the 5.0 and 25.0 mM [Mg2+] cardioplegic groups were not altered compared with control. These differences were most pronounced at the higher concentrations of U-46619 tested (Fig. 3).
|
Intrinsic myogenic contraction was observed to a stepwise increase in
the transmural pressure >50 mmHg in control vessels. In vessels from
higher [Mg2+] groups,
similar myogenic contractions were observed, but cardioplegia caused an
upward shift in the active pressure-diameter relation (both
P < 0.05 vs. control). However, the
myogenic contractions were abolished in the lower
[Mg2+] groups (both
P < 0.05 vs.
[Mg2+] 5.0 and 25.0 mM; Fig. 4).
|
| |
DISCUSSION |
|---|
|
|
|---|
Changes in [Ca2+]i and Vascular Contraction During Hyperkalemic Cardioplegia
Despite the fact that magnesium has been shown to protect the myocardium and coronary vasculature from hyperkalemic cardioplegia-related cardiac injury, its effect on regulating intracellular Ca2+ in coronary microvessels has not been well elucidated. The present study provides experimental evidence that a hyperkalemic cardioplegia containing a physiological concentration of Mg2+ (1.2 mM) causes a marked intracellular Ca2+ accumulation and significant vascular contraction, whereas a higher concentration of Mg2+ (>5.0 mM) can prevent this Ca2+ overloading and contraction during hyperkalemic cardioplegia.The mechanism responsible for the hyperkalemic cardioplegia-related [Ca2+]i accumulation in vascular smooth muscle is most likely related to membrane depolarization on the basis of Nernst's equation (17). Membrane depolarization promotes Ca2+ influx through voltage-dependent Ca2+ channels. Ca2+ influx also induces release of Ca2+ from intracellular Ca2+ stores (4). In addition, during surgical cardioplegia, especially using nonoxygenated crystalloid cardioplegic solutions, coronary microvessels are exposed to conditions of hypoxia. This is associated with a lower production of ATP compared with a normoxic state. It is widely recognized that [Ca2+]i is elevated during and after periods of hypoxia. In previous studies, it was suggested that transsarcolemmal Ca2+ influx via Na+/Ca2+ exchange may play an important role in hypoxia/reoxygenation-mediated Ca2+ accumulation (12, 22). Recently, other investigators have reported that Ca2+ release from the sarcoplasmic reticulum may contribute to hypoxic pulmonary vasoconstriction (6, 10).
High Mg2+ concentration has been suggested to inhibit Ca2+ entry into the cell by displacing Ca2+ from binding sites in the calcium channels and by hyperpolarization of sarcolemmal membrane (9). It has also been postulated that extracellular Mg2+ acts by raising intracellular Mg2+ concentration, thereby reducing the release of Ca2+ from the sarcoplasmic reticulum (3, 24). In addition, supplementation of Mg2+ in cardioplegic solutions may diminish the depletion of ATP stores, thereby protecting the intracellular metabolic function of microvascular smooth muscle. Accordingly, it seems that multiple cellular mechanisms may be involved in these beneficial actions of Mg2+ supplementation.
Indeed, it should be noted that the present study examined the effects of hyperkalemic cardioplegic solutions containing a physiological concentration of calcium (CaCl2 1.2 mM). Therefore, it is possible that a reduced Ca2+ concentration in a hyperkalemic cardioplegia might require a lower level of Mg2+ supplementation to achieve microvascular protection from intracellular Ca2+ overload. In clinical practice, however, it is more difficult to precisely regulate the cardioplegic Ca2+ concentration because of transient variables such as pH and temperature. As a result, patients are at risk of exposure to higher than originally intended Ca2+ levels, which may increase the likelihood of the Ca2+-mediated vascular injury. In addition, further decreasing the Ca2+ level may cause a calcium paradox in coronary microvessels. Therefore, we emphasize that the addition of Mg2+ may solve this dilemma by allowing for the safe use of higher cardioplegic Ca2+ concentrations, and we recommend sufficient supplementation of Mg2+ (>5.0 mM) in hyperkalemic cardioplegic solutions.
Changes in Vascular Contractility After Hyperkalemic Cardioplegia
One purpose of this study was to develop a better understanding of the pathophysiology in microvascular contractile dysfunction after hyperkalemic cardioplegia. In the present study, we demonstrated that in the lower [Mg2+] groups the agonist (U-46619)-induced vascular contraction was markedly enhanced, whereas the intrinsic myogenic contractile response was significantly diminished. Conversely, in higher [Mg2+] groups the agonist-induced and myogenic responses were preserved. (Figs. 3 and 4). Although the explanations for these phenomenon remain unclear, they may be attributed to endothelial dysfunction or altered contractile properties of vascular smooth muscle, or both.We and others (15, 20) have previously showed a progressive deterioration of the endothelial-dependent relaxation in the coronary microcirculation after surgical cardioplegia. Furthermore, our observations in this study are in agreement with the findings of Pearson and associates (16), who showed that hypomagnesemia could impair the release of nitric oxide from the coronary endothelium and promote vasoconstriction. In addition, we have previously reported that a Mg2+-based cardioplegic solution ([Mg2+] 25.0 mM) prevents much of the impairment in endothelium-dependent relaxation observed after exposure of microvessels to a purely hyperkalemic cardioplegic solution (23). Therefore, it is likely that hyperkalemic cardioplegia without sufficient Mg2+ supplementation may impair the endothelial function, including the release of nitric oxide, and predispose the patient to vascular hypercontraction in response to a vasoconstrictive agonist. Accordingly, it would be tempting to speculate that sufficient Mg2+ supplementation would afford endothelial protection, although the present study was not designed to provide direct evidence about functional implication of the endothelium.
It may also be possible that enhanced Ca2+ accumulation in the vascular smooth muscle may activate a Ca2+-dependent intracellular signaling pathway and alter the Ca2+ sensitivity of the contractile apparatus. Previous studies have demonstrated that an agonist-induced vascular tone is regulated by myosin light chain kinase, the activity of which is governed by a Ca2+-calmodulin-mediated phosphorylation (19). There is some evidence that [Ca2+]i may also directly activate the Ca2+-dependent isoforms of protein kinase C (conventional protein kinase C) and lead directly or indirectly to the phosphorylation of an entirely different subset of cellular proteins, including caldesmon, a number of intermediate filament proteins (desmin, synemin), and a few cytosolic proteins (18). Therefore, it is reasonable to propose that the [Ca2+]i overloading during cardioplegia is a strong trigger for enhancement of agonist-induced vascular contraction after reperfusion.
Myogenic tone is a property of vascular smooth muscle manifested by contraction in response to the increase in transmural pressure and is involved in the autoregulation of coronary perfusion. Although not completely understood, the contribution of adenosine triphosphate-sensitive potassium (K+ATP) channels to myogenic contraction was recently implicated (11). The K+ATP channels open when the intracellular ATP concentration falls to <1 mM (21). Opening of the K+ATP channels causes membrane hyperpolarization and relaxes the vascular smooth muscle by preventing Ca2+ entry via voltage-sensitive Ca2+ channels. In a previous study, the K+ATP channel blocker glibenclamide preserved myogenic reactivity after hyperkalemic cardioplegia (26). Taken together these observations and the results of the present study strongly suggest that supplementation with a higher concentration of Mg2+ (>5.0 mM) may inhibit activation of K+ATP channels by preventing intracellular ATP depletion in vascular smooth muscle and preserving the intrinsic myogenic contraction.
Methodological Considerations
The present study was designed to monitor intracellular Ca2+ accumulation and vascular function during and after hyperkalemic cardioplegia. This in vitro microvascular model uses a hypoxic, hyperkalemic cardioplegic solution that simulates the insufficient oxygen supply with crystalloid cardioplegia in the operating room. In this study, we aimed to address the efficacy of Mg2+ supplementation with the view of coronary microcirculatory protection. Coronary microvascular injury in stressed hearts is extremely important, because this microvascular function may be more vulnerable and sensitive to surgical hyperkalemic cardioplegia compared with myocardial function. Hyperkalemic cardioplegia-related coronary microcirculatory dysfunction in the setting of minimal changes in myocardial contractile function using a cardiopulmonary bypass model has recently been reported (23).There are a number of Ca2+-sensitive indicators, such as aequorin, indo-1, and fura 2. In the present study, we used the fura 2 microscopic technique to monitor the real-time changes of [Ca2+]i in microvascular smooth muscle. Although fura 2 is useful for the evaluation of [Ca2+]i, it must be noted that determination of the absolute value of [Ca2+]i from the fura 2 fluorescence ratio is still problematic; it cannot be totally excluded that changes in background autofluorescence of microvessels, compartmentation of fura 2 into intracellular organelles such as sarcoplasmic reticulum, or the deesterized form of fura 2-AM cause fluorescence signals unrelated to [Ca2+]i. For quantification of [Ca2+]i, we used an in situ dual-wavelength calibration by obtaining Rmax and Rmin and thus estimated cytosolic [Ca2+]i. In these calibration experiments, Rmin was highly consistent and reproducible with little variation; Rmax, however, was more variable. Similar variability in Rmax values has been previously reported (14). The variation in Rmax values may be related to limited effectiveness of the calcium ionophore 4-bromo-A23187 in this microvascular model. Although the [Ca2+]i values in the present study were similar to those reported by other investigators (2, 14), they may have to be revised when better methods to calibrate fura 2 fluorescence become available.
In conclusion, we have demonstrated that supplementation of >5 mM [Mg2+] possibly prevents hyperkalemic cardioplegia-related intracellular Ca2+ overloading and preserves vascular function in coronary microvessels. To protect coronary microcirculation from Ca2+-related vasospasm under cardiac surgery, these findings appear to be significant and clinically relevant and require further investigation for the development and manipulation of pharmacological strategies.
| |
ACKNOWLEDGEMENTS |
|---|
The authors express gratitude to Prof. Shigetsugu Ohgi (Tottori, Japan) for the continuous encouragement.
| |
FOOTNOTES |
|---|
This study was supported by National Heart, Lung, and Blood Institute Grants HL-46716 (to F. W. Sellke) and HL-31704 (to K. G. Morgan).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: F. W. Sellke, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, East Campus, Dana 905, 330 Brookline Ave., Boston, MA 02215 (E-mail: fsellke{at}bidmc.harvard.edu).
Received 13 July 1998; accepted in final form 9 December 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Altura, B. M.,
and
B. T. Altura.
New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I. Experimental aspects.
Magnesium
4:
245-271,
1985[Medline].
2.
Batlle, D. C.,
R. Peces,
M. S. LaPointe,
M. Ye,
and
J. T. Daugirgas.
Cytosolic free calcium regulation in response to acute changes in intracellular pH in vascular smooth muscle.
Am. J. Physiol.
264 (Cell Physiol. 33):
C932-C943,
1993
3.
Boland, R.,
A. Martonosi,
and
T. W. Tillack.
Developmental changes in the comparison and function of sarcoplasmic reticulum.
J. Biol. Chem.
249:
612-623,
1974
4.
Fabiato, A.
Simulated calcium current can both cause calcium loading in and trigger the calcium release from the sarcoplasmic reticulum of skinned cardiac cell.
J. Gen. Physiol.
85:
291-320,
1985
5.
Geffin, G. A.,
T. R. Love,
W. G. Hendren,
D. F. Torchiana,
J. S. Titus,
B. E. Redonnett,
D. D. O'Keefe,
and
W. M. Daggett.
The effect of calcium and magnesium in hyperkalemic cardioplegic solutions on myocardial preservation.
J. Thorac. Cardiovasc. Surg.
98:
239-250,
1989[Abstract].
6.
Gelband, C. H.,
and
H. Gelband.
Ca2+ release from intracellular stores is an initial step in hypoxic pulmonary vasoconstriction of rat pulmonary artery resistance vessels.
Circulation
96:
3647-3654,
1997
7.
Grynkiewicz, G.,
M. Poenie,
and
R. Y. Tsien.
A new generation of Ca2+ indicators with greatly improved fluorescent properties.
J. Biol. Chem.
260:
3440-3450,
1985
8.
Kronon, M.,
K. S. Bolling,
B. S. Allen,
S. Rahman,
T. Wang,
A. Halldorsson,
and
H. Feinberg.
The relationship between calcium and magnesium in pediatric myocardial protection.
J. Thorac. Cardiovasc. Surg.
114:
1010-1019,
1997
9.
Lansman, J. B.,
P. Hess,
and
R. Tsien.
Blockade of current through single calcium channels by Cd2+, Mg2+, and Ca2+: voltage and concentration dependence of calcium entry into the pore.
J. Gen. Physiol.
88:
321-347,
1986
10.
Liu, X.,
R. M. Engelman,
Z. Wei,
N. Maulik,
J. A. Rousou,
J. E. Flack, III,
D. W. Deaton,
and
D. K. Das.
Postischemic deterioration of sarcoplasmic reticulum: warm vs. cold blood cardioplegia.
Ann Thorac Surg
56:
1154-1159,
1993[Abstract].
11.
Loutzenhiser, R.,
and
M. Parker.
Hypoxia inhibits myogenic reactivity of renal afferent arterioles by activating ATP-sensitive K+ channels.
Circ. Res.
74:
861-869,
1994
12.
Matsuda, N.,
T. Mori,
H. Nakamura,
and
M. Shigekawa.
Mechanisms of reoxygenation-induced calcium overload in cardiac myocytes: dependence on pHi.
J. Surg. Res.
59:
712-718,
1995[Medline].
13.
McDonagh, P. F.,
and
H. Laks.
Use of cold blood cardioplegia to protect against coronary microcirculatory injury due to ischemia and reperfusion.
J. Thorac. Cardiovasc. Surg.
84:
609-618,
1982[Abstract].
14.
Meininger, G. A.,
D. C. Zawieja,
and
J. C. Falcone.
Calcium measurement in isolated arterioles during myogenic and agonist stimulation.
Am. J. Physiol.
261 (Heart Circ. Physiol. 30):
H950-H959,
1991
15.
Nakanishi, K.,
Z. Q. Zhao,
J. Vinten-Johansen,
J. C. Lewis,
D. S. McGee,
and
J. W. Hammon, Jr.
Coronary artery endothelial dysfunction after global ischemia, blood cardioplegia, and reperfusion.
Ann. Thorac. Surg.
58:
191-199,
1994[Abstract].
16.
Pearson, P. J.,
P. R. Evora,
J. F. Seccombe,
and
H. V. Schaff.
Hypomagnesemia inhibits nitric oxide release from coronary endothelium; protective role of magnesium infusion after cardiac operations.
Ann. Thorac. Surg.
65:
967-972,
1998
17.
Powell, T.,
P. E. R. Tatham,
and
V. W. Twist.
Cytosolic free calcium measured by quin-2 fluorescence in isolated ventricular myocytes at rest and during potassium-depolarization.
Biochem. Biophys. Res. Commun.
122:
1012-1020,
1984[Medline].
18.
Rasmussen, H.,
Y. Takuwa,
and
S. Park.
Protein kinase C in the regulation of smooth muscle contraction.
FASEB J.
1:
177-185,
1987[Abstract].
19.
Sasaguri, T.,
T. Itoh,
M. Hirata,
K. Kitamura,
and
H. Kuriyama.
Regulation of coronary artery tone in relation to the activation of signal transducers that regulate calcium homeostasis.
J. Am. Coll. Cardiol.
9:
1167-1178,
1987[Abstract].
20.
Sellke, F. W.,
T. Shafique,
F. J. Schoen,
and
R. M. Weintraub.
Impaired endothelium-dependent coronary microvascular relaxation following cold potassium cardioplegia and reperfusion.
J. Thorac. Cardiovasc. Surg.
105:
52-58,
1993[Abstract].
21.
Standen, N. B.,
J. M. Quayle,
N. W. Davies,
J. E. Brayden,
Y. Huang,
and
M. T. Nelson.
Hyperpolarizing vasodilators activate ATP-sensitive K+ channel in arterial smooth muscle.
Science
245:
1770-1780,
1989.
22.
Tani, M.,
and
J. R. Neely.
Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H+-Na+ and Na+-Ca2+ exchange.
Circ. Res.
65:
1045-1056,
1989
23.
Tofukuji, M.,
A. Stamler,
J. Y. Li,
A. Franklin,
S. Y. Wang,
M. D. Hariawala,
and
F. W. Sellke.
Effects of magnesium cardioplegia on regulation of the porcine coronary circulation.
J. Surg. Res.
68:
233-239,
1997.
24.
Tsukube, T.,
J. D. McCully,
M. Federman,
I. B. Krukenkamp,
and
S. Levitsky.
Developmental differences in cytosolic calcium accumulation associated with surgically induced global ischemia: optimization of cardioplegic protection and mechanism of action.
J. Thorac. Cardiovasc. Surg.
112:
175-184,
1996
25.
Wang, S. Y.,
M. Friedman,
R. G. Johnson,
R. M. Weintraub,
and
F. W. Sellke.
Adrenergic regulation of coronary microcirculation after extracorporeal circulation and crystalloid cardioplegia.
Am. J. Physiol.
267 (Heart Circ. Physiol. 36):
H2462-H2470,
1994
26.
Wang, S. Y.,
M. Friedman,
A. Franklin,
and
F. W. Sellke.
Myogenic reactivity of coronary resistance arteries after cardiopulmonary bypass and hyperkalemic cardioplegia.
Circulation
92:
1590-1596,
1995
This article has been cited by other articles:
![]() |
J. Zhang, W. G. Wier, and M. P. Blaustein Mg2+ blocks myogenic tone but not K+-induced constriction: role for SOCs in small arteries Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2692 - H2705. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Hoenicke, X. Sun, R. G. Strange Jr, and R. J. Damiano Jr Donor heart preservation with a novel hyperpolarizing solution: Superior protection compared with University of Wisconsin solution J. Thorac. Cardiovasc. Surg., October 1, 2000; 120(4): 746 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Stowe, S. G. Varadarajan, J. An, and S. C. Smart Reduced Cytosolic Ca2+ Loading and Improved Cardiac Function After Cardioplegic Cold Storage of Guinea Pig Isolated Hearts Circulation, September 5, 2000; 102(10): 1172 - 1177. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Matsuda, K. G. Morgan, and F. W. Sellke Effects of pinacidil on coronary Ca2+-myosin phosphorylation in cold potassium cardioplegia model Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H882 - H888. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tofukuji, N. Matsuda, C. Dessy, K. G. Morgan, and F. W. Sellke INTRACELLULAR FREE CALCIUM ACCUMULATION IN FERRET VASCULAR SMOOTH MUSCLE DURING CRYSTALLOID AND BLOOD CARDIOPLEGIC INFUSIONS J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 163 - 172. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |